TY - JOUR
T1 - Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives
AU - Sewastjanow-Silva, Matheus
AU - Yamashita, Kohei
AU - Rosa Vicentini, Ernesto
AU - Hirschmann, Meita
AU - Pool Pizzi, Melissa
AU - Trail, Allison Michelle
AU - Waters, Rebecca E.
AU - Rogers, Jane E.
AU - Ajani, Jaffer A.
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Introduction: Gastroesophageal cancers (GEC) are frequently found at the advanced stage. GEC treatment advancements have been limited and prognosis, therefore, remains poor. Through numerous clinical trials, the addition of immune checkpoint inhibitors, including nivolumab, to conventional therapy has demonstrated a survival benefit. Areas covered: Here, we focus on the function of nivolumab in patients with advanced GECs. We discuss the most recent trials that led to nivolumab’s incorporation into therapy and pathways forward. Expert opinion: Nivolumab in combination with chemotherapy appears well tolerated, with only a small number of patients reporting severe toxicity; therefore, it may be possible to add additional biological agents to improve outcomes. A number of ‘nivolumab plus other agents’ is currently being investigated, and we anticipate continued advancement in GEC management in the coming years.
AB - Introduction: Gastroesophageal cancers (GEC) are frequently found at the advanced stage. GEC treatment advancements have been limited and prognosis, therefore, remains poor. Through numerous clinical trials, the addition of immune checkpoint inhibitors, including nivolumab, to conventional therapy has demonstrated a survival benefit. Areas covered: Here, we focus on the function of nivolumab in patients with advanced GECs. We discuss the most recent trials that led to nivolumab’s incorporation into therapy and pathways forward. Expert opinion: Nivolumab in combination with chemotherapy appears well tolerated, with only a small number of patients reporting severe toxicity; therefore, it may be possible to add additional biological agents to improve outcomes. A number of ‘nivolumab plus other agents’ is currently being investigated, and we anticipate continued advancement in GEC management in the coming years.
KW - Checkpoint inhibitor
KW - Gastroesophageal Cancer
KW - PD-1
KW - PD-L1
KW - immunotherapy
KW - nivolumab
KW - pembrolizumab
UR - http://www.scopus.com/inward/record.url?scp=85141175500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141175500&partnerID=8YFLogxK
U2 - 10.1080/14737140.2022.2139241
DO - 10.1080/14737140.2022.2139241
M3 - Article
C2 - 36266061
AN - SCOPUS:85141175500
SN - 1473-7140
VL - 22
SP - 1177
EP - 1181
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 11
ER -